Lyell Immunopharma (LYEL) Net Income towards Common Stockholders (2020 - 2026)

Lyell Immunopharma's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$42.1 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 21.38% year-over-year to -$42.1 million; the TTM figure through Mar 2026 stood at -$244.9 million (up 27.86% YoY), while the FY2025 annual figure was -$256.3 million, up 23.41% from the prior year.
• Net Income towards Common Stockholders came in at -$42.1 million for Q1 2026 at Lyell Immunopharma, up from -$125.0 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$11.3 million in Q4 2022 to a low of -$196.2 million in Q4 2024.
• A 5-year average of -$61.0 million and a median of -$52.4 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders soared 76.0% in 2022 and tumbled 362.66% in 2023, its largest moves.
• Lyell Immunopharma's Net Income towards Common Stockholders stood at -$11.3 million in 2022, then sank by 362.66% to -$52.4 million in 2023, then slumped by 274.31% to -$196.2 million in 2024, then jumped by 36.31% to -$125.0 million in 2025, then surged by 66.34% to -$42.1 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$42.1 million, -$125.0 million, and -$34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison